Key facts
- Notable investors include Tencent Investment, C&D Emerging Investment, Loyal Valley Capital, Bayland Capital, Hongfeng Capital — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Fanli Biotechnology
- ·The full record, as it builds
Funding rounds
No funding rounds for Fanli Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Fanli Biotechnology
Provider of biomedical research and experimental development services intended to advance preclinical scientific understanding and therapeutic exploration. The company offers structured experimental research frameworks, regulated laboratory research activities, and applied medical investigation capabilities, enabling research institutions and life science organizations with reliable studies and translational insight.
- Sector
- Healthcare
- HQ
- Wuhan, China
- Founded
- 2023
- Ownership
- Privately Held (backing)
Fanli Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Fanli Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Fanli Biotechnology in its N-PORT filings yet. We sweep new filings monthly.